Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 11Neoplasm Metastasis 4Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Ovarian Neoplasms 2Recurrence 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms 1Meningioma 1Malignant Female Reproductive System Neoplasm 1Lymphoma 1Leukemia 1Inflammatory Breast Neoplasms 1Hemangiosarcoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Ependymoma 1Endometrial Neoplasms 1Disease Progression 1Disease 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Lobular 1Breast Cancer With Brain Metastasis 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 64pembrolizumab 48Fluorouracil 44Capecitabine 38Nivolumab 33Leucovorin 32Paclitaxel 28Trastuzumab 19Docetaxel 18Cisplatin 18S 1 (combination) 16Bevacizumab 15Ramucirumab 13Irinotecan 13Drug Therapy 13tislelizumab 12Cyclophosphamide 12fludarabine 10Carboplatin 10Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 8sintilimab 8Specimen Handling 8Biopsy 8atezolizumab 7Surgical Procedures, Operative 7Gemcitabine 7zolbetuximab 6durvalumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stomach Neoplasms × neratinib × 1 year × Clear all
NCT06109467 2026-02-09

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
36 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05274048 2025-10-29

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Fox Chase Cancer Center

Phase 1 Recruiting
18 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡